Alumis Inc.
ALMS
株式のランク
#10174
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
株価
$6.41
最終同期: 2026-10-19
時価総額
$830.25M
変化（1日）
4.81%
変化（1年）
182.57%
国
US
取引 Alumis Inc. (ALMS)
カテゴリー
Healthcare
Alumis Inc.（ALMS）のP/S比率
October 2026 時点のP/S比率 TTM: 0.00
Alumis Inc. の最新の財務報告および株価によると、現在のP/S比率（TTM）は 0.00 です。2023 年末時点でのP/S比率は 0.00 でした。
Alumis Inc. の P/S 比率の履歴（2021 ～ 2026）
各年末時点のP/S比率
| 年 | P/S比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
同業他社のP/S比率
| 企業 | P/S比率 | P/S比率の差 | 国 |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
